ErbB2 down-regulates microRNA-205 in breast cancer

Biochemical and Biophysical Research Communications

Volumn 411, Issue 4, 2011, Pages 804-808

  Adachi, Ryohei ^a   Horiuchi, Shota ^a   Sakurazawa, Yoshiyuki ^a   Hasegawa, Takuya ^a   Sato, Koji ^a   Sakamaki, Toshiyuki ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

Author keywords

Breast cancer; ErbB2; MicroRNA; MiR 205

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; MICRORNA 205; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CARCINOGENESIS; CELL ANCHORAGE; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; FEMALE; HUMANS; MICRORNAS; RECEPTOR, ERBB-2;

EID: 80051571107     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.07.033     Document Type: Article

References (37)

1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
2. Kallioniemi O.P., Holli K., Visakorpi T., Koivula T., Helin H.H., Isola J.J. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. International Journal of Cancer 1991, 49:650-655.
3. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., Chan S., Grimes D., Anton A., Lluch A., Kennedy J., O'Byrne K., Conte P., Green M., Ward C., Mayne K., Extra J.M. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of Clinical Oncology 2005, 23:4265-4274.
4. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine 2005, 353:1673-1684.
5. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 2001, 344:783-792.
6. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., Goldhirsch A., Untch M., Mariani G., Baselga J., Kaufmann M., Cameron D., Bell R., Bergh J., Coleman R., Wardley A., Harbeck N., Lopez R.I., Mallmann P., Gelmon K., Wilcken N., Wist E., Sanchez Rovira P., Piccart-Gebhart M.J. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
7. Esteva F.J., Valero V., Booser D., Guerra L.T., Murray J.L., Pusztai L., Cristofanilli M., Arun B., Esmaeli B., Fritsche H.A., Sneige N., Smith T.L., Hortobagyi G.N. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 2002, 20:1800-1808.
8. Seidman A.D., Fornier M.N., Esteva F.J., Tan L., Kaptain S., Bach A., Panageas K.S., Arroyo C., Valero V., Currie V., Gilewski T., Theodoulou M., Moynahan M.E., Moasser M., Sklarin N., Dickler M., D'Andrea G., Cristofanilli M., Rivera E., Hortobagyi G.N., Norton L., Hudis C.A. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. Journal of Clinical Oncology 2001, 19:2587-2595.
9. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 2002, 20:719-726.
10. Ryan Q., Ibrahim A., Cohen M.H., Johnson J., Ko C.W., Sridhara R., Justice R., Pazdur R. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008, 13:1114-1119.
11. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., Ellis C., Casey M., Vukelja S., Bischoff J., Baselga J., O'Shaughnessy J. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology 2010, 28:1124-1130.
12. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., Untch M., Rusnak D.W., Spehar G., Mullin R.J., Keith B.R., Gilmer T.M., Berger M., Podratz K.C., Slamon D.J. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Research 2006, 66:1630-1639.
13. Spector N.L., Xia W., Burris H., Hurwitz H., Dees E.C., Dowlati A., O'Neil B., Overmoyer B., Marcom P.K., Blackwell K.L., Smith D.A., Koch K.M., Stead A., Mangum S., Ellis M.J., Liu L., Man A.K., Bremer T.M., Harris J., Bacus S. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. Journal of Clinical Oncology 2005, 23:2502-2512.
14. Tomasello G., de Azambuja E., Dinh P., Snoj N., Piccart-Gebhart M. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Review of Anticancer Therapy 2008, 8:1883-1890.
15. Eichhorn P.J., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., Beijersbergen R.L., Valero V., Seoane J., Bernards R., Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Research 2008, 68:9221-9230.
16. Liu L., Greger J., Shi H., Liu Y., Greshock J., Annan R., Halsey W., Sathe G.M., Martin A.M., Gilmer T.M. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Research 2009, 69:6871-6878.
17. Trowe T., Boukouvala S., Calkins K., Cutler R.E., Fong R., Funke R., Gendreau S.B., Kim Y.D., Miller N., Woolfrey J.R., Vysotskaia V., Yang J.P., Gerritsen M.E., Matthews D.J., Lamb P., Heuer T.S. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clinical Cancer Research 2008, 14:2465-2475.
18. Xia W., Bacus S., Husain I., Liu L., Zhao S., Liu Z., Moseley M.A., Thompson J.W., Chen F.L., Koch K.M., Spector N.L. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Molecular Cancer Therapeutics 2010, 9:292-299.
19. Chen C.Z. MicroRNAs as oncogenes and tumor suppressors. New England Journal of Medicine 2005, 353:1768-1771.
20. Kloosterman W.P., Plasterk R.H. The diverse functions of microRNAs in animal development and disease. Developmental Cell 2006, 11:441-450.
21. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., Hammond S.M. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
22. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology 2008, 10:593-601.
23. Farazi T.A., Spitzer J.I., Morozov P., Tuschl T. miRNAs in human cancer. Journal of Pathology 2011, 223:102-115.
24. Mattie M.D., Benz C.C., Bowers J., Sensinger K., Wong L., Scott G.K., Fedele V., Ginzinger D., Getts R., Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Molecular Cancer 2006, 5:24.
25. Iorio M.V., Casalini P., Piovan C., Di Leva G., Merlo A., Triulzi T., Menard S., Croce C.M., Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Research 2009, 69:2195-2200.
26. Baffa R., Fassan M., Volinia S., O'Hara B., Liu C.G., Palazzo J.P., Gardiman M., Rugge M., Gomella L.G., Croce C.M., Rosenberg A. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. Journal of Pathology 2009, 219:214-221.
27. Sempere L.F., Christensen M., Silahtaroglu A., Bak M., Heath C.V., Schwartz G., Wells W., Kauppinen S., Cole C.N. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Research 2007, 67:11612-11620.
28. Blenkiron C., Goldstein L.D., Thorne N.P., Spiteri I., Chin S.F., Dunning M.J., Barbosa-Morais N.L., Teschendorff A.E., Green A.R., Ellis I.O., Tavare S., Caldas C., Miska E.A. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biology 2007, 8:R214.
29. Greene S.B., Herschkowitz J.I., Rosen J.M. The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biology 2010, 7:300-304.
30. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., Croce C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Research 2005, 65:7065-7070.
31. Greene S.B., Gunaratne P.H., Hammond S.M., Rosen J.M. A putative role for microRNA-205 in mammary epithelial cell progenitors. Journal of Cell Science 2010, 123:606-618.
32. Wu H., Zhu S., Mo Y.Y. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Research 2009, 19:439-448.
33. Scott G.K., Goga A., Bhaumik D., Berger C.E., Sullivan C.S., Benz C.C. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. Journal of Biological Chemistry 2007, 282:1479-1486.
34. Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021.
35. Gandellini P., Folini M., Longoni N., Pennati M., Binda M., Colecchia M., Salvioni R., Supino R., Moretti R., Limonta P., Valdagni R., Daidone M.G., Zaffaroni N. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Research 2009, 69:2287-2295.
36. Yu J., Ryan D.G., Getsios S., Oliveira-Fernandes M., Fatima A., Lavker R.M. MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proceedings of the National Academy of Sciences USA 2008, 105:19300-19305.
37. Scaltriti M., Eichhorn P.J., Cortes J., Prudkin L., Aura C., Jimenez J., Chandarlapaty S., Serra V., Prat A., Ibrahim Y.H., Guzman M., Gili M., Rodriguez O., Rodriguez S., Perez J., Green S.R., Mai S., Rosen N., Hudis C., Baselga J. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proceedings of the National Academy of Sciences USA 2011, 108:3761-3766.